z-logo
Premium
The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease
Author(s) -
Glue Paul,
Schenker Steven,
Gupta Samir,
Clement Robert P.,
Zambas Demetris,
Salfi Margaret
Publication year - 2000
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.2000.00186.x
Subject(s) - ribavirin , pharmacokinetics , medicine , tolerability , cmax , liver disease , chronic liver disease , gastroenterology , pharmacology , liver function , population , adverse effect , hepatitis c virus , immunology , cirrhosis , virus , environmental health
Aims  The primary objective of this study was to describe the single dose pharmacokinetics of ribavirin in subjects with normal liver function and those with various degrees of stable chronic liver disease. Additionally this study assessed the safety and tolerability of ribavirin in this population. Methods  Single oral 600 mg doses of ribavirin were administered to healthy male and female volunteers ( n  = 6) and patients with stable chronic liver disease ( n  = 17), in a parallel group study. Pharmacokinetic sampling and tolerability assessments were performed up to 168 h post dose. Results  Single oral doses of 600 mg ribavirin were well tolerated by healthy volunteers and patients with varying degrees of hepatic dysfunction. Although mean C max increased with the severity of hepatic dysfunction, there was no change in extent of absorption or renal clearance of ribavirin. Conclusions  There are no pharmacokinetic reasons for initial dose adjustment of ribavirin in patients with hepatic dysfunction.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here